Free Trial

Avid Bioservices Q1 2024 Earnings Report

Avid Bioservices logo
$12.39 +0.01 (+0.08%)
As of 01/17/2025 04:00 PM Eastern

Avid Bioservices EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.04
Beat/Miss
Beat by +$0.01
One Year Ago EPS
$0.02

Avid Bioservices Revenue Results

Actual Revenue
$37.73 million
Expected Revenue
$34.00 million
Beat/Miss
Beat by +$3.73 million
YoY Revenue Growth
N/A

Avid Bioservices Announcement Details

Quarter
Q1 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avid Bioservices? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avid Bioservices and other key companies, straight to your email.

About Avid Bioservices

Avid Bioservices (NASDAQ:CDMO) operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

View Avid Bioservices Profile

More Earnings Resources from MarketBeat